Equities

Granules India Ltd

GRANULES:NSI

Granules India Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (INR)540.50
  • Today's Change-3.75 / -0.69%
  • Shares traded805.08k
  • 1 Year change+62.70%
  • Beta0.5633
Data delayed at least 15 minutes, as of Sep 20 2024 06:37 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Sep-23
  • 20-Jun-24
  • 18-Jul-24
  • 15-Aug-24
  • 12-Sep-24
Select bar for recommendation details.
Recommendations12-Sep-24
Buy3
Outperform1
Hold0
Sell0
Strong Sell0

Share price forecast in INR

The 4 analysts offering 12 month price targets for Granules India Ltd have a median target of 665.00, with a high estimate of 769.00 and a low estimate of 515.00. The median estimate represents a 22.19% increase from the last price of 544.25.
High41.3%769.00
Med22.2%665.00
Low-5.4%515.00

Dividends

In 2024, Granules India Ltd reported a dividend of 1.50 INR, equaling last years dividend. The 2 analysts covering the company expect dividends of 1.25 INR for the upcoming fiscal year, a decrease of 16.67%.
Div growth (TTM)0.00%
More ▼

Earnings history & estimates in INR

On May 18, 2022, earnings of 4.46 per share.
Average growth rate+2.84%
Granules India Ltd reported annual 2024 earnings of 16.72 per share on May 15, 2024.
Average growth rate+15.94%
More ▼

Revenue history & estimates in INR

of 11.76bn. This missed the 12.19bn estimate of the one analyst following the company.
Average growth rate+0.68%
Granules India Limited had revenues for the full year 2024 of 45.06bn. This was 0.12% below the prior year's results.
Average growth rate+15.15%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.